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Objectives. We sought to compare the angiographic outcome of
diabetic patients (treated with insulin or oral hypoglycemic
agents) after successful coronary angioplasty with that in nondi-
abetic patients. The analysis included the outcome of the dilated
(restenosis) and nondilated narrowings (disease progression).
Background. Recent data have confirmed that diabetes mellitus
is an important risk factor for long-term adverse events. These
adverse events are more common after balloon angioplasty than
after bypass surgery (Bypass Angioplasty Revascularization In-
vestigation [BARI]).
Methods. We examined retrospectively 353 coronary angio-
grams of 248 patients (55 diabetic, 193 nondiabetic) who were
referred for diagnostic angiography >1 month after successful
angioplasty (1.4 6 0.6 [mean 6 SD] repeat angiograms/patient).
Restenosis and disease progression/regression were compared
between groups by means of quantitative angiography.
Results. Baseline clinical and angiographic characteristics were
similar in both groups. There was a nonsignificant trend for a
higher restenosis rate of dilated narrowings in diabetic patients.
There were no significant changes between diabetic and nondia-
betic patients in the rates of progression and regression of
narrowings that were not dilated during the initial angioplasty.
The main difference was in the rate of appearance of new
narrowings: There was a 22% increase in the number of narrow-
ings on the follow-up angiogram in diabetic patients (38 new, 174
preexisting narrowings) compared with 12% (86 new, 734 preex-
isting narrowings) in nondiabetic patients (p < 0.004). Diabetes
mellitus and the performance of angioplasty in the artery had an
additive risk for development of new narrowings, which were
identified in 15 (16.9%) of 89 arteries with and 16 (13.2%) of 121
without angioplasty in diabetic patients and in 42 (12.7%) of 331
arteries with and 38 (7.3%) of 518 without angioplasty in nondi-
abetic patients (p 5 0.009).
Conclusions. The combination of diabetes mellitus and an
artery that was instrumented during balloon angioplasty is addi-
tive and increases the risk of formation of new narrowing in that
artery. This finding may explain the high adverse event rates
observed in diabetic patients in the angioplasty arm of the BARI
study, most of whom had angioplasty performed in at least two
arteries.
(J Am Coll Cardiol 1997;30:1420–5)
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Coronary artery bypass graft surgery and coronary balloon
angioplasty are two possible revascularization approaches for
patients with coronary artery disease. Randomized compari-
sons between these two methods, in patients suitable for both
approaches, have been recently published and reviewed (1–6).
In one of these studies (Bypass Angioplasty Revascularization
Investigation [BARI]) (1,7), subgroup analysis suggested that
the long-term outcome is better with coronary artery bypass in
diabetic patients, with a similar outcome reported in nondia-
betic patients. Diabetes mellitus is a poor prognostic factor for
all patients with coronary artery disease (8,9) and specifically
for those who undergo coronary artery bypass surgery (10,11)
or balloon angioplasty (12). However, it is not clear why
adverse outcomes should be more common in diabetic patients
after balloon angioplasty than after coronary artery bypass. In
the present report, we analyzed the angiographic findings in
diabetic and nondiabetic patients who underwent diagnostic
coronary angiography .1 month after successful coronary
angioplasty and compare them. The influence of diabetes
mellitus on restenosis of the dilated narrowings and on disease
progression of narrowings that were not dilated was examined
separately.
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Methods
Patients and angiographic procedure. Between September
1989 and August 1991 (within the time period of enrollment of
patients in BARI) 2,587 coronary angiography and 1,385
percutaneous transluminal coronary angioplasty procedures
were performed at the Hadassah University Hospital. In 572
cases, a previous angiogram obtained at least 1 month earlier
in our laboratory was available for comparison. Our study
comprised 353 pairs of coronary angiograms from 248 patients
(1.4 6 0.6 [mean 6 SD] repeat diagnostic angiograms/patient)
who underwent balloon angioplasty at the initial procedure.
Patients who underwent dilation of a bypass graft were ex-
cluded. Referral for angiography was made by the patient’s
attending physician according to common clinical practice:
stable or unstable angina or a myocardial infarction in 326
patients and planned angioplasty in 27 patients who initially
underwent only partial revascularization, with further angio-
plasty postponed .1 month (none of these patients partici-
pated in a research protocol that required angiographic
follow-up after angioplasty). The time interval between the
first and second catheterization was 250 6 305 days (25, 50 and
75 percentiles: 94, 172 and 333 days, respectively).
Coronary angiography was undertaken using 4.5-in. image
intensifier mode with an overframing lens to achieve maximal
optical magnification of the arteries. Multiple oblique views
were taken to define the details of each coronary narrowing.
Coronary balloon angioplasty was performed using standard
technique (in no patient was an alternative device, such as a
stent, atherectomy catheter or rotablator used).
Data analysis. Coronary angiograms were reviewed in
pairs by an experienced angiographer (Y.R.) who had no
knowledge of the patient’s clinical information (specifically,
whether the patient was diabetic or nondiabetic). The severity
of the stenosis was measured on a single end-diastolic frame in
the projection with the most severe stenosis by means of a high
magnification projector and mechanical calipers. A special
attempt was made to choose the same projection in the pair of
angiograms when analyzing each of the narrowings for 1) the
presence and severity of restenosis in the dilated narrowings,
and 2) progression/regression of narrowings not dilated during
the angioplasty procedure. Diameters were measured twice
(.6 months apart) in 54 narrowings by the same observer
(Y.R.), to assess the intraobserver variability. The second
measurement was performed in blinded manner with regard to
the specific frame or projection in which the initial measure-
ments had been made. The standard deviation of the difference
between the two measurements was 0.41 mm, 0.28 mm and
8.6% for normal arterial diameter, lumen narrowing diameter
and percent stenosis, respectively. A more detailed description
of the method of measurement appears elsewhere (13).
Definitions. Successful angioplasty was defined as ,50%
residual diameter stenosis without major complications (death,
emergency coronary artery bypass or Q wave myocardial
infarction). Restenosis was defined as .50% diameter stenosis
at follow-up angiography after successful angioplasty (in any
location that was subjected to balloon inflation during the
angioplastic procedure).
Progression/regression was defined as an increase/decrease in
diameter stenosis .20%. New narrowing was defined as .20%
diameter stenosis, present only on the second angiogram.
Progression/regression and new narrowing were defined only
for coronary artery sites that were not subjected to previous
balloon inflation (nondilated narrowing). We used the 20%
cutoff (2.5 times the standard deviation of the difference
between repeated measurements) to ensure that the difference
in the measured stenosis severity did not reflect an inaccuracy
in the method of measurement. This value has been used
previously by us (14) and others (15) to define a definite
change in diameter stenosis of a coronary narrowing.
The angioplasty artery was defined as one of the three major
coronary arteries (including major branches) in which at least
one narrowing was dilated by angioplasty. Nondilated narrow-
ings were classified according to their relation to the angio-
plasty artery (14).
Statistical analysis. Data were analyzed using SAS soft-
ware. Chi-square and t tests were used for between-group
comparisons. The rate of appearance of new narrowings over
time was compared among groups by means of life-table
analysis. In the life table, each new narrowing was counted at
the time of its detection (the second catheterization). The
Kaplan-Meier method was used to construct life tables, and the
log-rank test was used for comparisons among groups. Treated
diabetes mellitus was defined as diabetes involving the use of
insulin or oral hypoglycemic agents; p , 0.05 was considered
statistically significant.
Results
Baseline angiography. Table 1 describes the clinical and
angiographic baseline characteristics of the study patients (55
with and 193 without diabetes mellitus). There was no differ-
ence in the number of narrowings/angiogram (an index of
diffuse disease) between groups (2.5 in diabetic, 2.6 in nondi-
abetic patients). The lumen diameter of the normal artery was
slightly smaller, the minimal lumen diameter of the narrowings
significantly smaller and percent diameter stenosis slightly
higher in diabetic than nondiabetic patients. Initial revascular-
ization tended to be more complete in diabetic patients: 60%
of all narrowings and 1.27 6 0.48 arteries/patient were dilated
after the initial angiogram (vs. 53% of narrowings and 1.17 6
0.45 arteries/patient in nondiabetic patients: p 5 0.11 for
narrowings, p 5 0.09 for arteries/patient). However, although
the normal artery and minimal lumen narrowing diameters of
dilated narrowings were similar in diabetic and nondiabetic
patients, they were significantly smaller in the nondilated
narrowings of diabetic patients.
Follow-up angiography. Table 2 describes the findings at
follow-up angiography. The rate of restenosis was slightly
higher (although not statistically significant) in diabetic pa-
tients, but the severity of the narrowings with restenosis was
similar in the two groups. The rates of progression and
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regression of narrowings were similar in diabetic and nondia-
betic patients; however, narrowings with progression reached a
higher percent stenosis in diabetic patients (91% vs. 74%, p 5
0.03).
The main difference between diabetics and nondiabetic
patients was in the appearance of new narrowings (Table 2).
There was a 22% increase in the number of narrowings on the
follow-up angiogram in diabetic patients (38 new, 174 preex-
isting narrowings) compared with 12% (86 new, 734 preexist-
ing narrowings) in nondiabetic patients (p , 0.004). The
number of new narrowings was higher in diabetic patients
when measured either per patient or per angiographic pair.
Even though according to our definition, a new narrowing
could have been a mild, nonsignificant lesion (close to 20%
diameter stenosis), most of these narrowings were important,
with a mean diameter stenosis .60% and similar stenosis
severity in diabetic and nondiabetic patients (Table 2).
Effect of angioplasty on appearance of new narrowings. To
examine the effect of angioplasty on the appearance of new
narrowings (in diabetic and nondiabetic patients), we com-
pared the appearance rate of these new narrowings in the
angioplasty and nonangioplasty arteries. New narrowings were
located in 57 (13.6%) of 420 angioplasty arteries and in 54
(8.5%) of 639 nonangioplasty arteries (p 5 0.01). As we
showed before, new narrowings were more common in diabetic
patients (31 [14.8%] of 210 arteries) than in nondiabetic
patients (80 [9.4%] of 849 arteries, p 5 0.03). Figure 1
describes the proportion of arteries with new narrowings for
angioplasty versus nonangioplasty arteries in patients with and
without diabetes mellitus. The highest proportion (16.9%) was
observed in the angioplasty artery of diabetic patients; an
intermediate value was found in the nonangioplasty artery of
diabetic patients (13.2%) and in the angioplasty artery of
nondiabetic patients (12.7%); and the lowest proportion was
found in the nonangioplasty artery of nondiabetic patients
(7.3%, p 5 0.009). The findings were similar when the rate of
detection of new narrowings as a function of the time interval
between catheterizations was compared among groups using
the life-table method (Fig. 2).
Discussion
Coronary artery bypass graft surgery and coronary angio-
plasty are acceptable revascularization techniques for patients
Table 1. Clinical and Angiographic Characteristics at Baseline
(first angiogram)
Diabetic
Patients
(n 5 55)
Nondiabetic
Patients
(n 5 193)
p
Value
Age (yr) 59 6 9 58 6 11 NS
Male 45 (82) 153 (79) NS
Angiographic pairs* 70 (1.3) 283 (1.5) NS
All narrowings n 5 174 n 5 734
Per angiogram 2.49 6 1.5 2.59 6 1.4 NS
Normal diameter (mm) 2.96 6 0.63 3.06 6 0.65 0.07
Narrowing diameter (mm) 0.8 6 0.7 1.0 6 0.8 0.01
Stenosis (%) 71 6 22 68 6 24 0.06
Dilated narrowings† 104 (60) 392 (53) 0.11
Normal diameter (mm) 3.1 6 0.5 3.1 6 0.6 NS
Narrowing diameter (mm) 0.8 6 0.6 0.8 6 0.6 NS
Stenosis (%) 74 6 18 73 6 19 NS
Nondilated narrowings† 70 (40) 342 (47) 0.11
Normal diameter (mm) 2.7 6 0.7 3.0 6 0.7 0.005
Narrowing diameter (mm) 0.9 6 0.8 1.2 6 1.0 0.02
Stenosis (%) 67 6 26 63 6 29 NS
*Total number (mean per patient). †Number (% of all). Data presented are
mean value 6 SD or number (%) of patients, unless otherwise indicated.
Table 2. Angiographic Characteristics at Follow-Up
(second) Angiography
Diabetic
Patients
Nondiabetic
Patients p Value
Dilated narrowings n 5 104 n 5 392
Restenosis 43 (41.3) 136 (34.7) NS
Restenosis severity
Diameter (mm) 0.8 6 0.6 0.7 6 0.6 NS
Stenosis (%) 78 6 16 79 6 15 NS
Nondilated narrowings n 5 71 n 5 342
Progression 5 (7) 30 (9) NS
Diameter (mm) 2.9 6 0.6 3.1 6 0.9 NS
Initial stenosis (%) 36 6 9 40 6 15 NS
Final stenosis (%) 91 6 14 74 6 15 0.03
Regression 5 (7) 33 (10) NS
Diameter (mm) 2.4 6 1.2 2.9 6 0.6 NS
Initial stenosis (%) 74 6 20 70 6 27 NS
Final stenosis (%) 3 6 7 11 6 19 NS
New narrowings* 38 (22) 86 (12) , 0.004
Per patient 0.69 6 1.0 0.45 6 0.8 0.06
Per angiogram 0.54 6 0.9 0.30 6 0.6 0.03
Stenosis (%) 64 6 24 66 6 23 NS
*Number (% increase in number of narrowings on second angiogram
[calculated on the basis of total number of narrowings on first angiogram]). Data
presented are mean value 6 SD or number (%) of narrowings in group, unless
otherwise indicated.
Figure 1. Percent of arteries with new narrowings at follow-up angiog-
raphy after angioplasty. DM(1) 5 diabetic patients; DM(2) 5
nondiabetic patients; n 5 number of arteries in each group;
PTCA(1) 5 angioplasty artery; PTCA(2) 5 nonangioplasty artery.
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with obstructive coronary artery disease. Recent randomized
studies have shown that these two techniques have a similar
effect on mortality and myocardial infarction rates during
follow-up and that patients who undergo coronary angioplasty
required more repeat interventions (mainly due to restenosis)
(1–6). Subgroup analysis in one of these studies (BARI) (1)
showed that mortality is higher in diabetic patients randomized
to undergo angioplasty. As a result, a clinical alert was
published (7) advising physicians to recommend coronary
artery bypass rather than angioplasty in treated diabetic pa-
tients.
Stein et al. (12) analyzed the Emory University database to
determine the influence of diabetes mellitus on the early and
late outcome after angioplasty. Diabetic patients had a higher
rate of mortality and myocardial infarction and a greater need
for repeat revascularization. The variation between diabetic
and nondiabetic patients might be due to differences in base-
line variables, procedural outcome (including restenosis) or
rate of disease progression, alone or in combination.
Baseline variables. Coronary atherosclerosis is more ex-
tensive in diabetic than in nondiabetic patients (16,17). Mul-
tivessel disease is a common finding at autopsy and was
observed in .75% of asymptomatic diabetic patients (17).
However, diabetic patients who are selected for coronary
angioplasty form a special subset not representative of all
diabetic patients because patients with diffuse disease are not
considered suitable candidates for angioplasty. There was no
significant difference in our study group between patients with
and without diabetes in the number of narrowings/patient (a
measure of diffuse disease), and even though diabetic patients
tended to have smaller arteries with slightly more severe
diameter stenosis, the differences were small and of question-
able clinical significance. Other investigators (12) found
slightly more diffuse disease in the diabetic patients who
underwent angioplasty compared with nondiabetic patients,
but only one-third of them had multivessel disease (only 6.6%
with three-vessel disease), and there was no difference in left
ventricular ejection fraction. Thus, at least according to angio-
graphic criteria, the extent of atherosclerotic involvement is
similar in diabetic and nondiabetic patients who are selected
for balloon angioplasty. Therefore, even if baseline variables
have some contribution to the poor long-term outcome of
diabetic patients after angioplasty, they are not the major
determinant.
Procedural outcome and restenosis. Procedural outcome
and major in-hospital complications are similar in diabetic and
nondiabetic patients (12). This similarity is probably due to
better selection of the patients in both groups, so that the
success rate of coronary angioplasty is high and complications
rare. In our study, the dilated narrowings had similar normal
diameters and diameter stenosis in diabetic and nondiabetic
patients. Restenosis is probably more common in diabetic
patients (12,18–21) and can explain their higher rate of repeat
interventions during the first year after angioplasty (12).
However, other investigators (22,23) could not find an associ-
ation between diabetes mellitus and restenosis, suggesting that
even if diabetic patients have a higher restenosis rate, this
higher rate not sufficient to explain the observed difference in
long-term outcome. Moreover, although restenosis can explain
differences among groups within the first year after angio-
plasty, most of the difference in the long-term outcome be-
tween diabetic and nondiabetic patients occurred after the first
year (12). Additionally, restenosis is rarely associated with
myocardial infarction and death (24), so restenosis does not
explain the poor outcome of diabetic patients who underwent
angioplasty in BARI.
Disease progression. The curves comparing survival, free-
dom from myocardial infarction and freedom from bypass
surgery between diabetic and nondiabetic patients diverge
mainly .1 year after angioplasty (12). A similar finding is
observed in the survival curves of diabetic patients after
coronary angioplasty or bypass surgery in BARI (1). Adverse
events .1 year after intervention are usually explained by
disease progression. Our analysis shows that the main differ-
ence between diabetic and nondiabetic patients is in the rate of
appearance of new narrowings. New narrowings are more
frequently unstable and may be associated with death or
unstable angina and myocardial infarction (both of which
require frequently revascularization) (25,26). In a previous
study (15), we showed that new narrowings appear more
commonly in the angioplasty than the nonangioplasty artery.
This finding was also confirmed in the present study (13.6% vs.
8.5%, angioplasty vs. nonangioplasty arteries with new narrow-
ings—60% increased risk), and we also showed that new
narrowings appeared more often in diabetic patients (14.8%
vs. 9.4% of arteries with new narrowings in diabetic vs.
nondiabetic patients—57% increased risk). The combined
effect of angioplasty and diabetes mellitus is additive (16.9%
vs. 7.3% of angioplasty arteries of diabetic patients vs. nonan-
gioplasty arteries of nondiabetic patients—132% increased
risk); thus, the risk of development of new narrowings in the
angioplasty artery of diabetics is especially high.
We suggested that mechanical trauma to the artery during
angioplasty could accelerate disease progression and the ap-
Figure 2. Rate of appearance of new narrowings in the various groups
presented as a function of the time interval between coronary angio-
plasty and follow-up angiography. Abbreviations as in Figure 1.
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pearance of new narrowings in angioplasty arteries, whereas
normalization of flow rate and pattern, especially in arteries
without restenosis, attenuated the rate of atherosclerosis pro-
gression in these arteries (15). New narrowings appeared in
that study (15) more commonly in the angioplasty artery both
proximal and distal to the site of balloon inflation, but the
numbers were too small to conclude whether proximal location
is associated with a higher risk. Diabetic patients may exhibit
accelerated intimal hyperplasia in response to vascular injury.
Such proliferative response has been seen in the mesangium of
the kidney in diabetic patients (27). Insulin induces growth of
human vascular smooth muscle cells (28), and the hyperinsu-
linemia in treated diabetic patients (both insulin-dependent
and noninsulin-dependent diabetes mellitus) might be respon-
sible for the higher rate of appearance of new narrowings (in
angioplasty and nonangioplasty arteries). We believe that the
balance between response to trauma and normalization of flow
(by coronary angioplasty) determines the final tendency of the
artery to demonstrate disease progression in both diabetic and
nondiabetic patients. An accelerated rate of atherosclerosis
progression and appearance of new narrowings are seen in
angioplasty and nonangioplasty arteries, but since the effect of
diabetes mellitus and angioplasty is additive, the risk is espe-
cially high in the angioplasty arteries of diabetic patients.
Comparison between coronary angioplasty and bypass sur-
gery in diabetic patients. Although this study analyzed only
the outcome of coronary angioplasty in diabetic patients, our
findings can offer a clue to the better long-term outcome of
diabetic patients after bypass surgery than after angioplasty
(1). The prognosis of diabetic patients with coronary artery
disease is poor compared with nondiabetic patients regardless
of the method of treatment (medical therapy, angioplasty or
coronary artery bypass) (8–12,29). When various treatment
modalities are randomly compared among diabetic patients
(e.g., angioplasty and bypass surgery), baseline variables are
usually similar because of the randomization process. Varia-
tions between the therapeutic strategies should be expected if
1) there is a difference in procedural outcome, or 2) the
procedure itself accelerates the progression of atherosclerosis,
above the general tendency for accelerated atherosclerosis that
is well known in diabetic patients. Because there was no
difference in immediate outcome between bypass surgery and
angioplasty in diabetic patients (1), the observed difference in
BARI can be explained not only by a higher restenosis rate
diabetic patients, but also by our finding of the additive effect
of diabetes mellitus and angioplasty on new lesion formation.
This effect is specific to angioplasty, and a higher risk in
patients with at least two coronary arteries instrumented
during the angioplastic procedure (most of the BARI popula-
tion) should be expected.
Limitations of the study. This was a retrospective study.
Patients had their second catheterization only when clinically
indicated. Patients with restenosis or disease progression, or
both, are thus overrepresented in our study (both diabetic and
nondiabetic patients). To overcome the variations in the time
interval between catheterizations, we used the life-table
method and analyzed the appearance of each new narrowing
according to the time of its detection. The retrospective design
of this study introduces two other potential sources of error: 1)
No specific attempt was made to control for changes related to
variation in coronary tone, although most our patients received
pretreatment with a combination of oral nitrates and a calcium
channel blocking agent. 2) Although angiograms were re-
viewed in pairs and a special attempt was made to use similar
projections to assess the severity of a specific narrowing on
both angiograms, the exact positions of the X-ray gantry in the
first angiogram were not reproduced during the later study.
Recognizing these sources of inaccuracy, we elected to use a
20% cutoff for the definition of disease progression/regression.
We believe that this large value allows for a wide margin of
safety and ensures specific determination of progression/
regression. However, these limitations preclude sensitive de-
tection of subtle changes in coronary narrowings.
Conclusions. The combination of diabetes mellitus and an
artery that was instrumented during balloon angioplasty is
additive and increases the risk of formation of new narrowing
in that artery. This finding may explain some of the high
adverse event rates observed in diabetic patients in the angio-
plasty arm of the BARI study, most of whom had at least two
arteries/patient treated by angioplasty.
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